Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ARIA vs GERN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GERN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

GERN Overall Winner 6-Pillar Tally: ARIA 0 – 6 GERN Matrix Metrics: ARIA 1 – 9 GERN

As of Nov 16, 2026, Geron Corp (GERN) is the stronger overall head-to-head candidate over ARIA (ARIA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARIA carries a Unified Composite Score of 47.7/100 (HOLD) at $21.03 (N/M Forward P/E, N/A operating margin), whereas GERN carries 54.1/100 (HOLD) at $0.94 (48.3x Forward P/E, -7.2% operating margin).

  • Technical & Structure Timing Caution: ARIA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile GERN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARIA vs GERN
ARIA US Equity
ARIA
Institutional Equity
$21.03
-3.52% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.92β · 43% Vol
Unified Composite Score
47.7 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
GERN NASDAQ Head-to-Head Winner
Geron Corp
Pharmaceutical Preparations
$0.94
-2.6% 1D
Market Cap $623.0M
TTM Revenue $218M
Forward P/E 48.3x
Beta / 30D Vol 1.53β · 101% Vol
Unified Composite Score
54.1 / 100 HOLD
Tech 69.0 Fund 70.0 Flow 71.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.8%), weak momentum, RSI 39
RSI-14: 38.6 · SMA20: $1.03 · SMA50: $1.17

6-Pillar Scorecard Institutional Category Breakdown (ARIA 0 – 6 GERN)

Columns: Metric · ARIA · GERN
1. Valuation Multiples GERN
Forward P/E N/M 48.3x
Trailing P/E N/M 48.3x
PEG Ratio N/M N/M
EV / Revenue N/M 3.1x
2. Growth & Scale GERN
Revenue Growth (YoY) N/A +27.4%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $218M
Market Cap N/A $623.0M
3. Profitability & Quality GERN
Gross Margin N/A 62.5%
Operating Margin N/A -7.2%
Net Profit Margin N/A -22.0%
Return on Equity (ROE) N/A -20.1%
4. Balance Sheet & Cash Flow GERN
Cash Generation (TTM) N/A -$91M
Cash Flow Margin N/A -41.9%
Net Cash / Leverage N/A ROE $52M Net Debt (0.53x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning GERN
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 91.5% (17th %ile)
Put/Call OI Skew N/A 3.06x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat GERN
OpEx & R&D Intensity N/A 69.7% of Rev ($152M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARIA (1) vs GERN (9)
Institutional Metric ARIA GERN Criterion Row Edge
Market Capitalization
Scale
N/A $623.0M Larger Scale GERN
Trailing P/E Ratio
Valuation
N/M 48.3x Lower Multiple GERN
Forward P/E Ratio
Valuation
N/M 48.3x Lower Multiple GERN
Revenue Growth (YoY)
Growth
N/A +27.4% Higher Growth GERN
Operating Margin (TTM)
Profitability
N/A -7.2% Higher Margin GERN
Net Profit Margin
Profitability
N/A -22.0% Higher Margin GERN
Return on Equity (ROE)
Capital Efficiency
N/A -20.1% Higher ROE GERN
52-Week Range Position
Momentum
0% ($21–$27) 9% ($1–$2) Stronger Trend GERN
Beta / 30D Volatility
Risk Regime
1.92β · 43% Vol 1.53β · 101% Vol Lower Realized Risk ARIA
Unified Institutional Score
Composite Signal
47.7 / 100 (HOLD) 54.1 / 100 (HOLD) Higher Composite GERN
Trailing 12M Revenue (USD)
Operating Scale
N/A $218M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 62.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$91M ($52M Net Debt (0.53x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ARIA +7.95 pp
ARIA: -11.55% · GERN: -19.5%
3M Horizon ARIA +22.23 pp
ARIA: -16.21% · GERN: -38.44%
6M Horizon ARIA +19.39 pp
ARIA: -16.97% · GERN: -36.36%
1Y Horizon ARIA +19.39 pp
ARIA: -16.97% · GERN: -36.36%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARIA vs GERN. Trailing 12-month operating profitability (ARIA N/A vs GERN -7.2%) and valuation multiples (ARIA N/M vs GERN 48.3x Forward P/E) are benchmarked directly in Pillar 4 below.

ARIA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
GERN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$218M
Gross Margin62.5%
Op. Margin-7.2%
ROE / Fwd P/E-20.1% · 48.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARIA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ARIA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GERN BREAKDOWN
72d in phase · OBV NEUTRAL
Current IV 91.5%
IV Percentile 17th %ile
Put/Call OI Skew 3.06x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact GERN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARIA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GERN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $623.0M market capitalization and -7.2% operating margin.
OpEx & R&D Reinvestment 69.7% of Rev ($152M)
90D Engineering Disclosures 0 Published

Investor FAQ ARIA vs GERN Key Questions & Quantitative Answers

As of Nov 16, 2026, Geron Corp (GERN) is the stronger overall head-to-head candidate over ARIA (ARIA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARIA carries a Unified Composite Score of 47.7/100 (HOLD) at $21.03 (N/M Forward P/E, N/A operating margin), whereas GERN carries 54.1/100 (HOLD) at $0.94 (48.3x Forward P/E, -7.2% operating margin). Technical & Structure Timing Caution: ARIA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile GERN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GERN leads the Growth & Scale pillar: ARIA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with GERN at +27.4% YoY revenue growth and +0.0% YoY earnings growth on $218M TTM revenue (62.5% gross margin, -7.2% operating margin). On trailing 12-month operating scale, ARIA generates N/A in USD-normalized revenue versus $218M for GERN. In operating R&D and SG&A reinvestment, ARIA deploys N/A (0 90-day corporate R&D disclosures) versus 69.7% of Rev ($152M) (0 disclosures) for GERN.

GERN screens cheaper on headline valuation multiples. ARIA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GERN trades at 48.3x Forward P/E, 48.3x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (-41.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARIA (N/A ROE) versus GERN (-20.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ARIA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.92β · 43% Vol realized risk). By comparison, GERN carries 91.5% implied volatility (17th %ile, Compressed (<25th %ile)), a 3.06x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.53β · 101% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.